𝔖 Bobbio Scriptorium
✦   LIBER   ✦

123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders

✍ Scribed by Olivier Rascol; Ludwig Schelosky

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
672 KB
Volume
24
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post‐ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. ^123^I‐metaiodobenzylguanidine (MIBG) scintigraphy that visualizes catecholaminergic terminals in vivo is a biomarker used to detect cardiac sympathetic degeneration. Abnormal MIBG uptake has been consistently reported in Lewy body disorders. Some studies agree in the notion that increasing bradykinesia is related with an incremental cardiac sympathetic denervation, whereas tremor is not closely linked to cardiac denervation. “Atypical” parkinsonian syndromes, including Multiple System Atrophy, Progressive Supranuclear Palsy, and others, show modest reductions of cardial MIBG uptake. MIBG scintigraphy is moderately sensitive and specific in differentiating Parkinson's disease from such syndromes. Conversely, its sensitivity and specificity might be better in cognitively impaired patients, helping differential diagnosis between Dementia with Lewy Bodies, and Alzheimer disease. Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy. © 2009 Movement Disorder Society

📜 SIMILAR VOLUMES

Myocardial 123metaiodobenzylguanidine up
Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease
✍ Aldo Quattrone; Antonio Bagnato; Grazia Annesi; Fabiana Novellino; Letterio Morg 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB

## Abstract Myocardial ^123^Metaiodobenzylguanidine (MIBG) enables the assessment of postganglionic sympathetic cardiac innervation. MIBG uptake is decreased in nearly all patients with Parkinson's disease (PD). Our objective was to evaluate MIBG uptake in patients with genetic PD. We investigated

123I-MIBG cardiac scintigraphy in Lewy b
123I-MIBG cardiac scintigraphy in Lewy body–related disorders
✍ Giorgio Treglia; Antonio Bagnato; Daniela Di Giuda; Alessandro Giordano 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Although we are sympathetic to Reynolds and Slocum's concerns, 1 their editorial errs on several points. The authors cite deference to regulatory (presumably Food and Drug Administration) approval as a constraint. The FDA has long recognized broad physician discretion in using FDAapproved drugs or d

Cardiac [123I]metaiodobenzylguanidine sc
Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism
✍ Joong-Seok Kim; Phil-Hyu Lee; Kwang-Soo Lee; Jeong-Wook Park; Yeong-In Kim; Yong 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

## Abstract The purpose of our study was to prospectively evaluate cardiac [^123^I]metaiodobenzylguanidine (MIBG) uptake in patients with cerebrovascular disease (CVD) who develop clinical symptoms of vascular Parkinsonism (VP). A total of 19 consecutive patients who developed Parkinsonism during t

[123I] FP-CIT spect study in vascular pa
[123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease
✍ Jan Zijlmans; Andrew Evans; Flavia Fontes; Regina Katzenschlager; Svetoslav Gaci 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB

## Abstract There is substantial evidence to support a role for small vessel disease (SVD) as a cause for vascular parkinsonism (VP). Using [^123^I] FP‐CIT SPECT (single photon emission computed tomography), we have tried to determine whether VP patients have pre‐synaptic dopaminergic function simi

Analysis of the relationship between mus
Analysis of the relationship between muscle sympathetic nerve activity and cardiac 123I-metaiodobenzylguanidine uptake in patients with Parkinson's disease
✍ Kazumasa Shindo; Eri Kaneko; Harue Watanabe; Tetsuhiko Sugimoto; Emiko Ohta; Ken 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 1 views

## Abstract To analyze the correlation between muscle sympathetic nerve activity (MSNA) and cardiac ^123^I‐metaiodobenzylguanidine (MIBG) uptake in patients with Parkinson's disease (PD), we measured both parameters in 14 PD patients who were 51 to 82 years of age (mean, 63.1 ± 8.7 years). The dura

Parkinson's syndrome and Parkinson's dis
Parkinson's syndrome and Parkinson's disease in mitochondrial disorders
✍ Josef Finsterer 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB

## Abstract In the majority of cases, mitochondrial disorders are multisystem conditions that most frequently affect the skeletal muscle, followed by the central nervous system. One of the clinical manifestations of central nervous system involvement is Parkinson's syndrome (PS). Evidence for an as